元の名称記録: Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis; Stichting VU

The invention relates to methods for tumor marker analysis comprising providing a genomic DNA sample from tumor cells of a patient, preselecting a chromosomal region on the genomic DNA comprising at least part of a potential structural variant (SV); and sequencing the genomic region to characterize the potential SV. The invention further relates to methods for detecting minimal residual disease, monitoring treatment response and tumor progression in a patient by employing the SV, and to personalized therapy based on the identity of the SV.